Physician profile
Mark R Doman
NPI 1013913391
$1,178.27
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $212 · 2021: $338 · 2022: $286 · 2023: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $161.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $497.92 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $193.82 | 2021-2023 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $142.57 | 2021-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $132.83 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $45.26 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $45.16 | 2021-2023 | Mounjaro |
| Pfizer INC. | $28.91 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.49 | 2023 | Xifaxan |
| Dexcom, INC. | $15.32 | 2021 | |
| Medline Industries LP | $15.17 | 2022 | |
| Vanda Pharmaceuticals INC. | $13.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.66 | 2021 | |
| Allergan, INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Doman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.